Correction to: Review of Transthyretin Silencers, Stabilizers, and Fibril Removal Agents in the Treatment of Transthyretin Cardiac Amyloid

On page 2 of the original publication, in the section onTTR Silencers dosing of patisiran in the APOLLO study was stated as being given every 3  months; this is inaccurate as patisiran was dosed every 3 weeks in the APOLLO study.

Source: Current Cardiology Reports - September 27, 2020 Category: Cardiology Source Type: research